2018 News Releases

Webcast ImageWebcast - Replay
AtriCure, Inc. at Morgan Stanley Global Healthcare Conference
09/14/18 at 1:00 p.m. ET
AtriCure, Inc. at Morgan Stanley Global Healthcare Conference
Friday, September 14, 2018 1:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
AtriCure, Inc. at Canaccord Genuity 38th Annual Growth Conference
08/09/18 at 12:00 p.m. ET
AtriCure, Inc. at Canaccord Genuity 38th Annual Growth Conference
Thursday, August 9, 2018 12:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
Q2 2018 AtriCure, Inc. Earnings Conference Call
08/01/18 at 4:30 p.m. ET
Q2 2018 AtriCure, Inc. Earnings Conference Call
Wednesday, August 1, 2018 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
08/28/18AtriCure Announces Completion of Patient Enrollment in the CONVERGE IDE Clinical Trial
Landmark study is the first prospective, randomized study comparing the Convergent approach to endocardial catheter ablation in persistent and long-standing persistent atrial fibrillation patients MASON, Ohio--(BUSINESS WIRE)--Aug. 28, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has completed enrollment of the full cohor... 
Printer Friendly Version
08/21/18AtriCure to Present at the Morgan Stanley Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Aug. 21, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt Hotel in New York on Friday, September 14, 2018. Management is scheduled to present at 1:00 p.m. Eastern Time. A live audio webcast of the presentation... 
Printer Friendly Version
08/01/18AtriCure Reports Second Quarter 2018 Financial Results
Updates 2018 Financial Outlook Worldwide revenue of $51.8 million – an increase of 14.5% year over year U.S. revenue of $40.8 million – an increase of 14.9% year over year International revenue of $11.0 million – an increase of 13.1% year over year Positive adjusted EBITDA of $0.8 million MASON, Ohio--(BUSINESS WIRE)--Aug. 1, 2018-- AtriCure, Inc.... 
Printer Friendly Version
07/16/18AtriCure to Present at the Canaccord Genuity 38th Annual Growth Conference
MASON, Ohio--(BUSINESS WIRE)--Jul. 16, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Canaccord Genuity 38th Annual Growth Conference at the Intercontinental Hotel in Boston on Thursday, August 9, 2018. Management is scheduled to present at 12:00 p.m. Eastern Time. A live audio webcast of t... 
Printer Friendly Version
07/11/18AtriCure to Announce Second Quarter 2018 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Jul. 11, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2018 financial results on Wednesday, August 1, 2018. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, August 1, 2018 to discuss its second quarter 2018 financial ... 
Printer Friendly Version
06/12/18AtriCure Announces 2018 Analyst and Investor Meeting
MASON, Ohio--(BUSINESS WIRE)--Jun. 12, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, will host an analyst and institutional investor meeting on Tuesday, June 26, 2018, in New York City from 8:30 a.m. to approximately 10:00 a.m. Eastern Time. The meeting will focus on clinician guest speakers to provide expert perspectives on broad trends in ... 
Printer Friendly Version
06/05/18AtriCure and Baheal Group Establish Partnership and China Distribution Agreement
Baheal will serve as the exclusive distribution partner for AtriCure products across China MASON, Ohio--(BUSINESS WIRE)--Jun. 5, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has partnered with Baheal Pharmaceutical Group in China to distribute AtriCure’s surgical ablation devices. This new multi-year agreement establishes... 
Printer Friendly Version
04/26/18AtriCure Reports First Quarter 2018 Financial Results
Worldwide revenue of $47.0 million – an increase of 13.9% year over year U.S. revenue of $38.4 million – an increase of 15.5% year over year International revenue of $8.6 million – an increase of 6.9% year over year MASON, Ohio--(BUSINESS WIRE)--Apr. 26, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (... 
Printer Friendly Version
04/05/18AtriCure to Announce First Quarter 2018 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Apr. 5, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2018 financial results on Thursday, April 26, 2018. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, April 26, 2018 to discuss its first quarter 2018 financial re... 
Printer Friendly Version
03/15/18AtriCure to Present at the Needham & Company’s 17th Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Mar. 15, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Needham & Company’s 17th Annual Healthcare Conference at the Westin Grand Central in New York on Tuesday, March 27, 2018. Management is scheduled to present at 1:30 p.m. Eastern Time. A live audio webcast ... 
Printer Friendly Version
02/26/18AtriCure Reports Fourth Quarter and Full Year 2017 Financial Results
2017 worldwide revenue of $174.7 million – an increase of 12.6% year over year 2017 U.S. revenue of $138.4 million – an increase of 13.1% year over year 2017 international revenue of $36.3 million – an increase of 11.0% year over year MASON, Ohio--(BUSINESS WIRE)--Feb. 26, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib)... 
Printer Friendly Version
02/22/18AtriCure Launches the AtriClip® FLEX•V™ Device in the United States
New device builds on the “V” clip technology, offering increased flexibility in left atrial appendage management MASON, Ohio--(BUSINESS WIRE)--Feb. 22, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has launched the AtriClip FLEX•V™ Left Atrial Appendage (LAA) Exclusion System in the United States. The new AtriCli... 
Printer Friendly Version
02/20/18AtriCure Names Scott Drake Board Chairman
Richard Johnston and Elizabeth D. Krell, Ph.D. are Retiring from the Board of Directors in May MASON, Ohio--(BUSINESS WIRE)--Feb. 20, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that Scott Drake has been named Board Chairman, effective at the annual meeting in May of this year. Concurrent with this appointment... 
Printer Friendly Version
02/07/18AtriCure to Announce Fourth Quarter and Full Year 2017 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Feb. 7, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2017 financial results on Monday, February 26, 2018. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Monday, February 26, 2018 to discuss its fourth quarter and fu... 
Printer Friendly Version
01/08/18AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2017
MASON, Ohio--(BUSINESS WIRE)--Jan. 8, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the fourth quarter and full year 2017 and provided 2018 financial guidance. Preliminary and unaudited revenue for fourth quarter 2017 is expected to be approximately $46.1 million, reflecting growth of... 
Printer Friendly Version